Expectations meet reality when companies have to show their cards during earnings season.
While the hype surrounding the legal cannabis sector has been enormous, pot stock earnings reports crushed expectations.
That's a great sign for pot stock investors. But there's still time to get in early if you're sitting on the sidelines.
The Dow Jones Todayh will be up in anticipation of the March FOMC meeting.
The Federal Reserve is not expected to raise interest rates, but investors are more interested in Fed Chair Jerome Powell's statements on winding down the balance sheet.
Investors are pulling back as the Department of Transportation launches an investigation into the Federal Aviation Administration's approval of 737 MAX 8 planes.
More on how this, U.S.-China trade news, and updates to monetary policy are affecting the Dow.
Recreational marijuana companies have become some of the hottest investments on Wall Street.
But medical marijuana companies get far less ink, even though many of them are likely to be more profitable.
We're extremely bullish on medical marijuana stocks because the medical industry is expanding as much as recreational cannabis. In fact, Global Market Insights projects that the market for medical marijuana will exceed $8 billion in the United States by 2024.
Money Morning Defense and Tech Specialist Michael Robinson believes that $8 billion figure is likely conservative.
Recreational marijuana makes plenty of headlines, and for good reason.
On top of that, the medical cannabis sector is also a growing industry.
There are some innovative companies who see the undeniable upside in serving both market segments – recreational and medical.
Here’s how it’s a win-win strategy for them and investors…
by Greg Miller
We've seen time and again how "takeover targets" provide the opportunity for truly explosive gains. The right company finds the right buyer, and investors gleefully strap in for a virtually instantaneous double- or triple-digit ride.
Dealmaking in general has done some "exploding" of its own over the past few years. 2018 broke records, with some $3.3 trillion worth of dried ink in place by September. That figure was bolstered by the advent of so-called "megadeals" worth more than $5 billion.
Companies have finally figured out the mother of all corporate no-brainers: If you can't beat 'em… buy 'em.
They've realized there's no point in throwing millions (or billions) of your – scratch that, your shareholders' – dollars at a thorny R&D, tech, or PR problem when you can just ride out, find some smaller company that's already done the work, and… acquire, acquire, acquire.
So, when we come across a frenzy of M&A activity in an already rapidly growing, high-profit sector like legal cannabis, it pays to stop and take a good hard look at what's happening.
Let's take a look at how powerful a moneymaker marijuana deals could be next year...
How on earth did anyone miss out on the most exciting thing to hit the stock market since the dot-com craze in the 1990s?
The whole point of investing in stocks is to be compensated for taking the significant risk of losing capital.
And the marijuana industry is providing investors some of the biggest returns on the market now.
Now, two new catalysts are poised to take the industry even higher...
The Dow Jones Industrial Average is finally seeing some signs of life as it's made gains over the last two days. And the rally is on track to keep rolling today.
The Dow Jones projected a 35-point gain in premarket hours as Wall Street is finally seeing tensions relax between the U.S. and China over trade.
Should I Buy Airbnb stock?
That's what a lot of investors are asking themselves heading into 2019.
You can get the answer right here...
This is the first week of cannabis earnings reports since Canada fully legalized all marijuana use on Oct. 17.
The reports could be a bellwether for just how lucrative legalization will be for cannabis stocks in 2019.
